Ewa E Chelmicka-Schorr

Title: Ewa E Chelmicka-Schorr: Innovator in Autoimmune Disease Treatment

Introduction

Ewa E Chelmicka-Schorr is a notable inventor based in Chicago, IL (US). She has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. Her innovative approach utilizes .beta.-adrenergic agonists, which has shown promising results in clinical trials.

Latest Patents

Ewa holds a patent for the "Use of .beta.-adrenergic agonists to treat patients with demyelinating diseases." This invention discloses improved methods for treating autoimmune diseases using .beta.-adrenergic agonists, specifically .beta..sub.2 -adrenergic agonists. The treatment of animals with either EAE or EAN using the .beta..sub.2 -adrenergic agonist terbutaline significantly suppressed clinical disease. A Phase I safety treatment trial with terbutaline was conducted in MS patients, where twenty-four patients were treated for four weeks. No obvious side effects were observed, and at the end of the trial, 15 of the 24 patients improved on the neurologic rating scale, while 17 patients reported subjective improvement.

Career Highlights

Ewa is associated with Arch Development Corporation, where she continues to advance her research and innovations. Her work has been instrumental in exploring new treatment avenues for patients suffering from autoimmune conditions.

Collaborations

Ewa has collaborated with esteemed colleagues such as Barry G Arnason and Anthony Thomas Reder, contributing to the advancement of research in her field.

Conclusion

Ewa E Chelmicka-Schorr's innovative work in the treatment of autoimmune diseases highlights her dedication to improving patient outcomes. Her contributions through patents and collaborations continue to pave the way for future advancements in medical science.